IFNA1 and multiple sclerosis: In addition, an IFN-α mutant (YNS) and its engineered forms with increased binding affinity for type I IFN receptors exhibited not only higher anti-proliferative activity than IFN-β but also had therapeutic effect in an animal model of multiple sclerosis (Harari et al., 2014).